I would just add, in that particular context, that one of the concerns is abuse of process when it happens. If you can deal with those concerns, that may lubricate the wheel and allow us to move forward on some of these recommendations.
On other specific recommendations, the issue is far more delicate. Oftentimes IP policy is driven by the pharmaceutical industry, and then you have very complex trade-offs between what is currently a vibrant generic industry in Canada and brand-name manufacturers, and their implications for provincial health care funders. Those are far more complicated and perhaps not quite as easy to deal with.